Nicox revenues total €7 million through first 9 months of year

Nicox reported €7 million in revenues in the first 9 months of this year compared with €3.2 million in the same period of 2014, according to a press release. “The first 9 months of 2015 were marked by the continuous growth of our European commercial operations, which increased by 119% over the same period of 2014, and as well as by the new drug application acceptance for filing of Vesneo, our leading nitric oxide-donating candidate partnered with Valeant in glaucoma,” Michele Garufi, CEO and chairman of Nicox, said in the release.